About Us

• Established JW Therapeutics.

• Licensed JWCAR129, a BCMA-targeted CAR-T therapy for multiple myeloma.

• Submitted the IND application for relma-cel in China.

• Acquired Syracuse, expanding the pipeline with a cell therapy candidate for hepatocellular carcinoma (HCC).
• Listed on the Main Board of HKEX (Stock Code: 2126.HK).

• Received NMPA approval for Carteyva® (relmacabtagene autoleucel injection), China's first Class 1 CAR-T cell 

• Received approval for the sNDA of Carteyva® for follicular lymphoma (FL).
• Initiated the clinical study of JWATM204 in advanced HCC, with the first patient infused.
• Established strategic collaborations with 2seventy bio (MAGE-A4 TCR-T) and Juno Therapeutics (DLL3-targeted cell therapy). 

• Initiated the clinical study of JWATM214 in advanced HCC, with the first patient infused.
• Established a strategic collaboration with 2seventy bio for autoimmune disease (AID) cell therapy.

• Received NMPA approval for Carteyva® in relapsed or refractory mantle cell lymphoma (MCL).

• Entered into an sLVV technology licensing agreement with Juno Therapeutics, marking the international licensing of JW Therapeutics' proprietary suspension lentiviral vector (sLVV) technology. 
• Signed an amendment to the strategic collaboration agreement with Regeneron. 
• Carteyva® received marketing approval from the Pharmaceutical Administration Bureau of the Macao SAR. 
• Carteyva® was included in the first National Healthcare Security Administration (NHSA) Commercial Health Insurance Innovative Medicines Catalog.

Relma-cel (research code: JWCAR029) is marketed under the brand name Carteyva® (relmacabtagene autoleucel injection).